(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Stanford University
Novartis
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Mayo Clinic
Novartis
National Cancer Institute (NCI)
M.D. Anderson Cancer Center